Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998128 | 0.85 | EGFR (0.55) | EGFRHSD17B10TDO2 | |
| SCHEMBL27906316 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2NOTUMBAZ1A | |
| SCHEMBL27474117 | 0.81 | EGFR (0.59) | EGFRIMPDH2TDO2HDAC1HDAC6 | |
| SCHEMBL27694201 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2NOTUMBAZ1A | |
| SCHEMBL3822753 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2NOTUMBAZ1A | |
| SCHEMBL3971054 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2NOTUMBAZ1A | |
| SCHEMBL12064494 | 0.81 | EGFR (0.55) | EGFRIMPDH2TDO2NOTUMHDAC1 | |
| SCHEMBL30754672 | 0.80 | GAA (0.49) | EGFRHSD17B10IMPDH2NOTUMBAZ1A | |
| SCHEMBL10923754 | 0.80 | EGFR (0.49) | EGFRIMPDH2TDO2NOTUMHDAC1 | |
| SCHEMBL27868899 | 0.80 | GAA (0.49) | EGFRHSD17B10IMPDH2NOTUMBAZ1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1178938-C | 1,2-annelated quinoline derivatives | ղɭҩҵ����˾ | 2004-12-08 | — | — | CN | claimed |
| CN-1331693-A | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-16 | — | — | CN | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | disclosed |
| CN-103459384-A | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS INC | 2013-12-18 | — | — | CN | disclosed |
| CN-101267821-B | Use of FLT3 inhibitor and farnesyl transferase inhibitor for the preparation of a medicament for the synergistic modulation of FLT3 kinase | JANSSEN PHARMACEUTICA NV | 2012-05-09 | — | — | CN | disclosed |
| CN-101267821-A | Synergistic modulation of FLT3 kinase using FLT3 inhibitors and farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-17 | — | — | CN | disclosed |
| CN-101242846-A | Synergistic modulation of FLT3 kinase using thienopyrimidine and thienopyridine kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101242837-A | Synergistic modulation of FLT3 kinase with aminopyrimidine kinase modulators and farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101242838-A | Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101242845-A | Synergistic modulation of FLT3 kinase using a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101242847-A | Synergistic modulation of FLT3 kinase using aminopyrimidines kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| CN-1207296-C | Farnesyl transferase inhibiting 1, 2-annelated quinoline enantiomers | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-22 | — | — | CN | disclosed |
| CN-1178938-C | 1,2-annelated quinoline derivatives | ղɭҩҵ����˾ | 2004-12-08 | — | — | CN | disclosed |
| CN-1437601-A | Farnesyl transferase inhibiting 1, 2-annelated quinoline enantiomers | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-20 | — | — | CN | disclosed |
| EP-1322650-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| EP-1261343-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR NUCLEOSIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002024686-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| CN-1331693-A | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-16 | — | — | CN | disclosed |
| WO-2001064195-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR NUCLEOSIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |